GPON ONT STICK SFP

描述

Descriptions:

CRED’s GPON-ONU-SFP-KCSM series transceiver is a high performance module for single fiber communications using a 1310nm burst- mode transmitter and a 1490nm continuous-mode receiver. It is used in the optical network terminal (ONT) for GPON ONU Class B+ applications with Mac inside.

The Transmitter is designed for single mode fiber and operates at a nominal wavelength of 1310nm. The transmitter module uses a DFB laser diode with full IEC825 and CDRH class 1 eye safety.

The receiver section uses a hermetic packaged APD-TIA (APD with trans-impedance amplifier) and a limiting amplifier. The APD converts optical power into electrical current and the current is

transformed to voltage by the trans-impedance amplifier. The differential DATA and /DATA CML data signals are produced by the limiting amplifier.

CRED SFP transceiver could compliant with most of word brand products, like Cisco, Finisar, HP, Ericsson, Nortel Arista, Juniper, Extreme, Allied Telesis, Foundry, Force10, Alcatel-Lucent…and more.

Features

• Single fiber bi-directional data links asymmetric TX 1244Mbps / RX 2488Mbps GPON ONU application with GPON MAC function
• SC/UPC or SC/APC receptacle SFP with GPON ONU MAC inside, “Plug-and-play” via auto-discovery and configuration
• 1310nm DFB burst mode transmitter, 1490nm APD-TIA continuous mode receiver for 20km transmission
• 0 to 70°C operating case temperature for GPON-ONU-SFP-KCSM , C-Temp
• -40 to 85°C operating case temperature for GPON-ONU-SFP-KISM , I -Temp
• Single 3.3V power supply
• Digital diagnostic monitor interface compatible with SFF-8472
• SFP MSA compliance
• Low EMI and excellent ESD protection
• Class I laser safety standard IEC-60825 compliant
• RoHS-6 compliance

Applications

• Complies with SFP Multi-Source Agreement (MSA) SFF-8074i
• Complies with ITUT-T 984.2, G.984.2 Amendment 1
• Complies with ITUT G.988 ONU management and control interface (OMCI) specification
• Complies with SFF 8472 5
• Complies with FCC 47 CFR Part 15, Class B
• Complies with FDA 21 CFR 1040.10 and 11